3D Organoid Cell Culture - Optimising disease models for research and drug discovery
The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture.
Although advances in 3D cell culture systems are improving drug target validation and lead optimisation, it is the advancement of organoid cell culture that is making a significant impact in disease modelling and drug discovery.
In this article, we examine the use of organoid cell culture systems as applied to cancer research and the development of novel antioncologic drugs. Collectively, this transition from 3D spheroid culture to organoid culture allows researchers to generate multiple organ-specific cell types, resulting in cell architectures that more closely resemble the human tissue microenvironment. Furthermore, researchers are generating organoid cultures that are increasingly complex and more phenotypically relevant and, as a result, optimal models are being established to better understand patient-specific tumour proliferation and invasion patterns.
Increasingly-complex 3D models
As 3D cell culture has become more widely accepted, researchers have become more proficient with 3D techniques and the models being created have become more complex. Researchers now create spheroids made of multiple cells types (1), combine tools to create advanced co-culture models (2) and are recapitulating organs from stem cells, including human iPS (HiPSCs) cells to the form of organoids (3).
These recent advances in 3D cell culture and greater adoption of HiPSCs for basic research and drug discovery are coalescing to generate systems that provide numerous advantages over more traditional, established culturing systems. While 3D systems provide more in vivo-like tissue environments in which to study cell function, patientderived HiPSCs provide a better model of human disease pathophysiology than other model systems. Consequently, researchers can now better study the complex in vivo functionality of tissue and organ systems, and can monitor patient-specific response to treatment prior to clinical evaluation (4). As discussed in a prior issue of this publication, organoids – and more complex organ systems – are now being leveraged for lead optimisation, including estimations of compound preclinical toxicity and potential metabolic liability.
Using HiPSCs, several organoids have now been generated including brain (5), eye (6), intestine (7) (Figure 1), liver (8), lung (9), heart (10) and kidney (11) (summarised in Table 1). These models offer researchers a tool to better study tissue formation, renewal and function while maintaining many of the disease characteristics of the individual from which the cells were sourced (3).
3D cell culture and cancer research
Cancer researchers were among the first to adopt 3D cell culture systems, principally as development of 3D cell culture systems facilitates study of host-tumour interactions. In addition, progress has been made in the use of 3D cell systems in high throughput screening for cancer drug discovery and development.
A diverse array of model systems is available to investigate the disease mechanisms that promote tumorigenesis. Such systems range from simplistic 2D cultures that rarely recapitulate the true complexity of human cancer, to very expensive and complex mouse models that seldom reflect the pathophysiology of human tumour progression. In a climate where the clinical trial success rate for oncology drugs is only 3.4% (12), cancer researchers are adopting 3D culture techniques to study human cancer biology and develop novel, efficacious treatments for cancer patients.
While cancer cell organoids are typically derived from primary cells rather than HiPSCs, solid tumour models grown in 3D systems encourage cell-cell and cell-matrix interactions that closely imitate the natural environment. Compared to 2D cell culture systems, these models:
- Better mimic solid tumour gene and protein expression, metabolic activity, cell stress response, structure, signal transduction and cellular transport proteins (13).
- Exhibit patient variability and resistance to drug uptake and metabolism, and drug sensitivity (14).
- Reproduce most parameters of the tumour micro-environment, including oxygen and nutrient gradients, as well as the development of dormant tumour regions (13).
Two clear examples of these advantages can be found in research related to breast cancer. Pickl et al (15) demonstrated that breast tumours cultured in 3D express higher sensitivity to trastuzumab than those cultured in 2D, as the cells of the 3D cultures display increased activation and dependence on HER2 and HER3 signalling. Trastuzumab blocked HER2 and HER3 activation and proliferation of 3D cultures but not 2D-cultured cells.
Wenzel et al (16) used imaging technologies to distinguish the inner core of T47D breast cancer cells cultured in 3D from those in the outer core of the culture. Inner core cells had less access to oxygen and nutrients and showed reduced metabolic activity compared with outer core cells. By screening small molecule libraries against these 3D cell cultures, these authors (14) identified nine novel compounds that selectively killed the inner core cancer cells without affecting the more active proliferating outer core cancer cells.
The field is now moving toward more predictive 3D cancer models that utilise patient-derived tumours, as well as high throughput drug screening using these 3D models. Numerous methods have been reported that consistently produce 3D tumour organoids and that are compatible with HTS automation instrumentation, increasing the potential for large-scale drug screening using patient-derived tumour models (17).
Advances in neurological research
Nonetheless, the limitations of 2D cell culture are most clear in neurological research. Indeed, 2D cultures lack the complexity of the brain in terms of function and development (18).
While neural stem cells can differentiate successfully in both 2D and 3D cell culture formats, differentiated neural stem cell spheroids have been shown to present similar or stronger neuronal and glial signals than those grown in 2D cultures (Figure 2 and Figure 3).
Progress has also been made in generating HiPSC-derived neuronal organoids that display a level of self-organisation that is not recapitulated in 2D cell cultures, suggesting a promising advance in understanding neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease (19-21). Figure 4 illustrates the classification of brain models, from less complex 2D neural aggregates to highly complex in vivo animal models.
Three-dimensional cultures of HiPSC-derived neuronal cells have been generated in large-scale arrays and imaging technologies used to measure neurite outgrowth. HiPSC-derived neurons from patients with familial Alzheimer’s disease mutations can be grown in 3D cultures for at least eight weeks. It was shown that diseased neurons expressed several key proteins involved in Alzheimer’s disease neurodegeneration, including Aβ and phosphorylated tau protein. These data may provide a screening format to identify compounds acting to reduce the production of these disease-causing biomarkers (20).
Another recent study monitored the expression of A in 3D cell cultures of HiPSC-derived neurons from five different patients with familial Alzheimer’s disease. They measured the action of known inhibitors of β - and γ -secretase (enzymes responsible for generating neuronal Aβ), and cultured the neurons for up to nine weeks to generate more mature neurons for drug testing. The addition of β- and γ-secretase inhibitors lowered A levels in the neurons cultured in 3D, but their efficacy was markedly less than that in 2D cultures of the same cells – likely due in part to reduced bioavailability. It was also shown that neurons from a patient in which the -secretase inhibitors were ineffective lacked key proteins required for enzyme inhibition.
These data, and other reports, suggest that drug efficacy is affected by the variability in the cell genome and proteome of different patients. They also reiterate the advantage of 3D cell culture versus 2D cell culture as a predictor of human drug efficacy in vivo. This is particularly relevant given that -secretase inhibitors have now all failed to show efficacy in late-stage clinical trials (21). This also illustrates the importance of screening HiPSCderived neurons from multiple patients to estimate variations in clinical efficacy.
Patient-derived glioblastoma model (23)
Glioblastoma multiforme (GBM) is the most lethal, as well as the most common, type of primary brain tumor in adults. The research and drug development work focused on GBM has been limited by pre-clinical models that relay on cell autonomous in vitro models, or in vivo models that poorly simulate human disease. Tumours are complex systems that are greatly influenced by their host. While several 3D models of cancers have been developed, all are fundamentally limited and only address some aspects of GBM.
Patient-derived glioma stem cells (GSCs) are the accepted standard for studying GBM biology (22). This subpopulation of cells is the most phenotypically- relevant to the parental tumour, and is imperative for tumour initiation, maintenance and invasion. In addition, GSCs demonstrate an increased resistance to cytotoxic drugs and ionising radiation.
GSCs are not cell autonomous, however, but are instead greatly influenced by tumour host-cell interactions. Efforts to generate 2D co-cultures of GSCs with neurons, glia and other brain-specific cell types often result in disorganised cellular structures that are not representative of the human brain. Furthermore, while tumour organoids allow GSCs to grow within a 3D extracellular matrix, they do not address the criticality of the tumourhost tissue microenvironment interactions. A powerful tool has recently been developed for modelling human GBM, using human embryonic stem cell (hESC)- or iPSC-derived cerebral organoids and patient-derived GSCs (23). Linkous et al established GLICO (cerebral organoid glioma) models to retro-engineer patient-specific GBMs, resulting in tumours that closely mimic the patient’s original brain tumour.
Using Corning® Matrigel® as a 3D extracellular matrix, hESCs were differentiated into fullyformed cerebral organoids. GFP-labelled GSCs were then co-cultured with individual cerebral organoids for 24 hours. The tumour take rate was 100% for all GSC lines, and considerable tumour growth was detected one week after co-culture of the tumour-infiltrated organoids. Additionally, the tumour-bearing organoids recapitulated the tumour morphology found in human patient GBMs. The interrogation of the growth patterns of six patient-derived GSC lines in the model revealed dramatically differentiated patterns and degrees of tumour cell invasion and proliferation between the different lines. This differentiation reflects the heterogeneity of the invasive phenotypes clinically observed in patients.
The GLICO model addresses several limitations presented by prior models, allowing researchers to study patient-specific GBMs within a microenvironment like that of a human brain. Because it is grown ex vivo, the model can be used for experimental drug treatment. In addition, the model is scalable for high throughput drug screening, opening the possibility for successfully screening tumour cells for clinically active drugs and other interventions.
Summary and outlook
The culturing of human-derived tissues in 3D organoid systems presents a major advance in drug discovery and, specifically, the ability to successfully screen tumour cells in vitro for clinically active drugs. Compared to 2D cell culture, 3D cultures provide more architecturally-relevant barriers for compounds to pass through, a critical factor in determining efficacy. Additionally, 3D culture systems better model cell-cell interaction, a benefit most apparent in complex tissues such as the brain. Finally, the temporal aspect of 3D cell culture – which in many cases is long lived – is important when modelling diseases such as neurodegenerative diseases, which are often slow to develop.
As researchers have become more proficient with 3D techniques, the models being created have become more complex. Researchers can better study the in vivo functionality of tissue and organ systems, and monitor patient-specific response to treatment. The generation of organ-specific organoids using hPSCs are proving to be particularly powerful tools for cancer research as they allow for the study of organ development and tissue morphogenesis, as well as better modelling of diseases (24). These advances, along with those in high throughput screening, are leading to more clinically-relevant models.
In the future, researchers will likely continue to move more toward patient-specific treatments and personalised medicine. Technologies and methods such as those used to generate patient-specific organoids, renewable human tissue (24) and 3D bioprinted cancer models (25) are advancing and providing a window into the future.
Thank you to Dr Wesley (Lien-Yu) Hung of the Corning Research Center Taiwan for his neural stem cell spheroid data. DDW
This article originally featured in the DDW Spring 2019 Issue
Dr Amanda Linkous previously served as the Director of the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine (New York, NY). Dr Linkous is currently the Scientific Center Manager for the NCI’s Center for Systems Biology of Small Cell Lung Cancer (SCLC) at Vanderbilt University, where she is developing similar 3D model systems to study the biology and refractory nature of SCLC (Nashville, TN). She completed her postdoctoral training in the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD).
Hilary Sherman is a Senior Scientist in the Corning Life Sciences Applications Lab located in Kennebunk, ME. Hilary has been with Corning Incorporated since 2005 and has worked with a wide variety of cell types including mammalian, insect, primary and stem cells in a vast array of applications. Her key roles at Corning involve creating technical documents such as protocols and whitepapers as well as providing technical support and training for both the Corning sales force and customers. Hilary received her BS degree in Biology from the University of New Hampshire.
Mei (Iris) Li is Director, Global Scientific Applications and Support of Corning Life Sciences. Iris has been with Corning Life Sciences since 2008. She focuses on management of field applications support, technical call centres and technology centres. She has experience in developing a strong support base for product applications and ensuring the successful implementation of technology strategy in defined markets. Iris holds a Masters degree in Biology from the College of William and Mary.
Dr Richard M. Eglen is currently Vice-President and General Manager of Corning Life Sciences, an operating division of Corning Incorporated based outside of Boston, Massachusetts (USA). Dr Eglen has more than 40 years’ experience in the Life Sciences industry. Prior to joining Corning in 2011, he was President of bio-discovery at PerkinElmer and held other executive management positions in the pharmaceutical, diagnostic and biotech industries. Dr Eglen has extensive experience in drug discovery, including serving as Executive Vice-President for research and development at DiscoveRx Corp (now Eurofins Pharma Discovery Services), and as Vice-President of the Center for Biological Research at Roche Pharmaceuticals. At Roche, he was responsible for leading drug discovery programmes in the areas of cardiovascular disease, migraine, neuropathic pain and urinary tract disorders.
1 Lazzari, Gianpiero et al. Multicellular spheroid based on a triple co-culture: A novel 3D model to mimic pancreatic tumor complexity. Acta biomaterialia 78 (2018): 296-307.
2 Sherman, Hilary, Gitschier, Hannah J and Rossi, Ann Elizabeth. A Novel Three- Dimensional Immune Oncology Model for High- Throughput Testing of Tumoricidal Activity. Frontiers in immunology 9 (2018): 857.
3 Fatehullah, Aliya, Tan, Si Hui and Barker, Nick. Organoids as an in vitro model of human development and disease. Nature cell biology 18.3 (2016): 246.
4 Fang, Y, Eglen, RM. Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discovery. 2017, 22, 456-472.
5 Chen, H. Isaac, Song, Hongjun and Ming, Guo li. Applications of human brain organoids to clinical problems. Developmental Dynamics 248.1 (2019): 53-64.
6 Hallam, Dean et al. Human Induced Pluripotent Stem Cells Generate Light Responsive Retinal Organoids with Variable and Nutrient Dependent Efficiency. Stem Cells 36.10 (2018): 1535-1551.
7 McCracken, Kyle W et al. Generating human intestinal tissue from pluripotent stem cells in vitro. Nature protocols6.12 (2011): 1920.
8 Nie, Yun-Zhong et al. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure. Stem cell research & therapy 9.1 (2018): 5.
9 Dye, Briana R et al. In vitro generation of human pluripotent stem cell derived lung organoids. Elife 4 (2015): e05098.
10 Hoang, Plansky et al. Generation of spatial patterned early-developing cardiac organoids using human pluripotent stem cells. Nature protocols 13.4 (2018): 723.
11 Takasato, Er et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature (2015); 526(7574):564-8.
12 Wong CH, Siah, KW, Lo, AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2018;20(2):273-286.
13 Senkowski, W, Jarvius, M, Rubin, J et al. Large-scale gene expression profiling platform for identification of contextdependent drug responses in multicellular tumor spheroids. Cell Chem. Biol. 23(11), 1428-1438.
14 Stock, K, Estrada, MF, Vidic, S et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Sci Rep. 2016; 6: 28951.
15 Pickl, M and Ries, CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28: 461-468, 2009.
16 Wenzel, C et al. 3D highcontent screening for the identification of compounds that target cells in dormant tumor spheroid regions. Experimental cell research 323, 131-143.
17 Madoux, F, Tanner, A, Vessels, M. A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids. SLAS Discov. 2017, 22 (5), 516-524.
18 Jorfi, Mehdi et al. Three Dimensional Models of the Human Brain Development and Diseases. Advanced healthcare materials 7.1 (2018): 1700723.
19 Monzel, AS et al. Derivation of human midbrain-specific organoids from neuroepithelial stem cells. Stem Cell Rep. 8, 1144-1154 (2017).
20 Lee, HK et al (2016). Three dimensional human neurospheroid model of Alzheimer's disease based on differentiated induced pluripotent stem cells. PLoS ONE 11:e0163072.
21 Raja, WK et al. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate alzheimer's disease phenotypes. PLoS ONE 11, e0161969 (2016).
22 Lee, J, Kotliarova, S, Kotliarov, Y, Li, A, Su, Q, Donin, NM, Pastorino, S, Purow, BW, Christopher, N, Zhang, W, et al (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403.
23 Linkous, A et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep. 2019 Mar 19;26(12): 3203-3211.
24 Hay, DC, O’Farrelly, C. Designer human tissue: coming to a lab near you. Philos Trans R Soc Lond B Biol Sci. 2018;373(1750):20170212.
25 Zhang, YS, Duchamp, M, Oklu, R, Ellisen, LW, Langer, R, Khademhosseini, A. Bioprinting the Cancer Microenvironment. ACS Biomater Sci Eng. 2016;2(10):1710-1721.
26 Jo, J, Xiao, Y, Sun, AX et al. Midbrain-Like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell 2016, 19, 248-257.
27 Pasca, AM, Sloan, SA, Clarke, LE et al. Functional Cortical Neurons and Astrocytes from Human Pluripotent Stem Cells in 3D Culture. Nat. Methods 2015, 12, 671-678.
28 Mansour, AA, Gonçalves, JT, Bloyd, CW et al. An In Vivo Model of Functional and Vascularized Human Brain Organoids. Nat. Biotechnol. 2018, 36, 432-441.
29 Medda, X, Mertens, L, Versweyveld, S et al. Development of a Scalable, High-Throughput-Compatible Assay to Detect Tau Aggregates Using iPSC-Derived Cortical Neurons Maintained in a Three-Dimensional Culture Format. J. Biomol. Screen. 2016, 21, 804-815.
30 Choi, SH, Kim, YH, Quinti, L et al. 3D Culture Models of Alzheimer’s Disease: A Road Map to a Cure-in-a-Dish. Mol. Neurodegener. 2016, 11, 75-90.
31 Jorfi, M, D’Avanzo, C,Tanzi, RE et al. Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease. Sci. Rep. 2018, 8, 2450.
32 Zhong, X, Guiterrez, C Xue, T et al. Generation of Three-Dimensional Retinal Tissue with Functional Photoreceptors from Human iPSCs Nat. Commun. 2015, 5, 4047-4053.
33 Tzatzalos, E, Abeliz, OJ, Shukla, P et al. Engineered Heart Tissues and Induced Pluripotent Stem Cells: Macroand Microstructures for Disease Modeling, Drug Screening, and Translational Studies. Adv. Drug Deliv. Rev. 2016, 96, 234-244. 28.
34 Heubsch, N, Loskill, P, Deveshwar, N et al. Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses. Sci. Rep. 2016, 6, 24726.
35 Nath, S, Devi, G. Three-Dimensional Culture Systems in Cancer Research: Focus on Tumor Spheroid Model. Pharmacol. Ther. 2016, 163, 94-108.
36 Bian, W, Badie, N, Herman, DH et al. Robust T-Tubulation and Maturation of Cardiomyocytes Using Tissue- Engineered Epicardial Mimetics. Biomaterials 2014, 35, 3819-3828.
37 Hirt, MN, Sorensen, NA, Bartholdt, LM et al. Increased Afterload Induces Pathologic Cardiac Hypertrophy: A New In Vitro Model. Basic Res. Cardiol. 2012, 107, 307-312.
38 Nunes, SS, Miklas, JW, Liu, J et al. Biowire: A Platform for Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Nat. Methods 2013, 10, 781-787.
39 Mathur, A, Loskil, P, Shoa, K et al. Human iPSC-Based Cardiac Microphysiological System for Drug Screening Applications. Sci. Rep. 2015, 5, 8883.
40 Tiburcy, M, Didier, M, Boy, O et al. Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic Growth in Engineered Heart Tissue. Circ. Res. 2011, 109, 1105-1114.
41 Workman, MJ, Mahe, MM, Trisno, S et al. Engineered Human Pluripotent-Stem-Cell- Derived Intestinal Tissues with a Functional Enteric Nervous System. Nat. Med. 2017, 23, 49-59.
42 Zhang, RR, Koido, M, Tadokoro, T et al. Human iPSC Derived Posterior Gut Progenitors Are Expandable and Capable of Forming Gut and Liver Organoids. Stem Cell Rep. 2018, 10, 780-793.